
Pharmaceutical Research & Development | AbbVie
AbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives
Patient Assistance | AbbVie
AbbVie is committed to helping patients get the medicines they need. That’s why we offer patient assistance programs that provide free AbbVie medicines to qualifying patients. Our Patient …
Products | AbbVie
View names and safety data sheets for our products. The product information provided below is intended for residents of the U.S. only.
Patient Access and Affordability | AbbVie
Oct 24, 2024 · AbbVie help patients get the medicines and solutions they need through various access and support programs and services, including saving cards, bridge programs and patient assistance …
Contact Center | AbbVie
AbbVie’s Ethics Helpline is available 24 hours a day, seven days a week to raise concerns and report suspected or actual violations of our Code of Business Conduct, policies, procedures, or laws and …
Patients | AbbVie
Oct 24, 2024 · From drug discovery and development to ensuring our medicines are accessible and affordable, patient needs are what guide our work. We also create resources to help people taking …
Online Application Overview | AbbVie
Oct 24, 2024 · AbbVie Patient Access Support includes programs that provide access and financial support and treatment-related resources to patients. We can help identify financial assistance …
Opportunities | AbbVie
AbbVie has career opportunities in R&D, Corporate, Commercial, Operations, Aesthetics and IT. See where your skills can apply.
AbbVie News Center - News
AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults
AbbVie to Acquire Capstan Therapeutics, Further Strengthening ...
Jun 30, 2025 · Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells …